POMALYST

This brand name is authorized in United States. It is also authorized in Australia, Canada, Ecuador, Hong Kong SAR China, Japan, New Zealand, Singapore.

Active ingredients

The drug POMALYST contains one active pharmaceutical ingredient (API):

1	Pomalidomide UNII D2UX06XLB5 - POMALIDOMIDE
	Pomalidomide has direct anti-myeloma tumoricidal activity, immunomodulatory activities and inhibits stromal cell support for multiple myeloma tumour cell growth. Pomalidomide in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma.
	Read more about Pomalidomide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
POMALYST Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AX06		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AX Other immunosuppressants
Discover more medicines within L04AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10386P, 10387Q, 10406Q, 10417G
CA	Health Products and Food Branch	02419580, 02419599, 02419602, 02419610
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1574-MEE-1215, 1575-MEE-1215, 1576-MEE-1215, 1577-MEE-1215
HK	Department of Health Drug Office	64089, 64090, 64091, 64092
JP	医薬品医療機器総合機構	4291038M1026, 4291038M2022, 4291038M3029, 4291038M4025
NZ	Medicines and Medical Devices Safety Authority	17220, 17221, 17222, 17223
SG	Health Sciences Authority	14713P, 14714P, 14715P, 14716P
US	FDA, National Drug Code	59572-501, 59572-502, 59572-503, 59572-504